Previous 10 | Next 10 |
2023-10-02 11:41:56 ET More on SCYNEXIS Scynexis: From Fungal To Bungle, The Brexafemme Recall And A Slippery Slope (Rating Downgrade) Scynexis recalling antifungal therapy on potential contamination Seeking Alpha’s Quant Rating on SCYNEXIS Historical ...
The law firm of Kirby McInerney LLP is investigating potential claims against Scynexis, Inc. (“Scynexis” or the “Company”) (NASDAQ: SCYX). The investigation concerns whether Scynexis and/or certain of its officers have violated the federal securities laws and/or en...
JERSEY CITY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. is conducting a voluntary nationwide recall of 2 lots of BREXAFEMME ® (ibrexafungerp tablets) to the consumer level in the US market due to potential cross contamination with a non-antibacterial ß-lactam drug subst...
NEW YORK, NY / ACCESSWIRE / September 27, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of SCYNEXIS, Inc. ("SCYNEXIS" or "the Company") (NASDAQ:SCYX). Investors who purchased SCYNEXIS securities are encouraged to obtain additional informa...
2023-09-26 19:54:24 ET Summary We downgrade Scynexis to a sell rating following the voluntary recall of antifungal pill, Brexafemme. Historical precedence suggests that manufacturing recalls can take months to resolve, and for a single-product biotech, we see further downside to t...
2023-09-25 13:00:22 ET Gainers: Vaccitech plc ADR ( VACC ) +93% . ESS Tech ( GWH ) +23% . Flora Growth Corp ( FLGC ) +22% . Avalo Therapeutics ( AVTX ) +22% . Neuraxis ( NRXS ) +19% . American Coastal Insurance Corp ( ACIC ...
2023-09-25 09:20:13 ET More on Scynexis Seeking Alpha’s Quant Rating on SCYNEXIS Historical earnings data for SCYNEXIS Financial information for SCYNEXIS For further details see: Scynexis recalling antifungal therapy on potential contamination
JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that management will participate in the following investor conferen...
2023-08-16 08:33:15 ET Sacks Parente Golf ( SPGC ) -38% . Impel Pharmaceuticals ( IMPL ) -36% . SRM Entertainment ( SRM ) -22% announces pricing of its initial public offering . Coherent Corp. ( COHR ) -22% . after Q4 earning release . ...
2023-08-14 17:39:02 ET SCYNEXIS press release ( NASDAQ: SCYX ): Q2 GAAP EPS of $2.46 beats by $1.01 . Revenue of $131.5M (+9862.1% Y/Y) beats by $36.1M . Shares +2.14% AH. For further details see: SCYNEXIS GAAP EPS of $2.46 beats by $1.01, revenue...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...